相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699
Mika Naganawa et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study
Paivi Hirvensalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers
Bauke Schievink et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance
W. Byon et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3
Keiji Shimizu et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
PET imaging for receptor occupancy: meditations on calculation and simplification
Yumin Zhang et al.
JOURNAL OF BIOMEDICAL RESEARCH (2012)
First automatic radiosynthesis of 11C labeled Telmisartan using a multipurpose synthesizer for clinical research use
Hitoshi Iimori et al.
ANNALS OF NUCLEAR MEDICINE (2011)
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials
Frank A. Holtkamp et al.
EUROPEAN HEART JOURNAL (2011)
Reduction of proteinuria with angiotensin receptor blockers
Jan Galle
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies
P Aranda et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)